CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 175 enrolled / 175 target
Drug / intervention
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) +3 moredrug
Likely dose
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05767346
NCT05767346Phase 3CompletedMonitor (4.8/mo)Completion was 16mo ago
CompareCT.gov

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics·interventional·Posted Mar 14, 2023·Updated Jun 9, 2026

In Brief

A Phase 3 clinical trial evaluating Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, and 2 other interventions for Obstructive Hypertrophic Cardiomyopathy (oHCM). Completed, enrolled 175 participants across 71 sites in 13 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Hypertrophic Cardiomyopathy (oHCM)
CountriesBrazil, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, United Kingdom, United States
CollaboratorsSanofi

Timeline

Phase 3CompletedFinished
202420252026
First PostedMar 14, 2023
Enrollment StartJun 20, 2023
Primary CompletionFeb 28, 2025
Study CompletionMar 28, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.3 years ago

Arms & Interventions

Aficamten up to 20 mg plus placebo for metoprololexperimental

Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.

Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Drug: Placebo to match metoprolol succinate
Metoprolol succinate up to 200 mg plus placebo for aficamtenactive_comparator

Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.

Drug: Placebo to match aficamtenDrug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)

Interventions

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)drug

Aficamten (CK-3773274) tablets administered orally

Placebo to match aficamtendrug

Placebo for aficamten (CK-3773274) administered orally

Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)drug

Metoprolol succinate tablets administered orally

Placebo to match metoprolol succinatedrug

Placebo for metoprolol succinate administered orally